Axial spondyloarthritis (axSpA) Market and Forecast Analysis to 2037

Axial spondyloarthritis (axSpA) Market and Forecast Analysis to 2037

  • July 2018 •
  • 393 pages •
  • Report ID: 5780018 •
  • Format: PDF
Disease Overview
Axial spondyloarthritis (axSpA) is a chronic, systemic, inflammatory rheumatic disease that predominantly affects the spine and sacroiliac (SI) joints, leading to chronic back pain. The chronic inflammation can eventually result in new bone formation in the SI joints and spine, causing permanent impairment in spinal mobility. Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) are the two sub-diseases that comprise axSpA.

Market Snapshot

Uptake of IL inhibitors and US price increases will drive market growth despite downward pressure from biosimilars.
Biologic DMARDs are prescribed with increasing frequency as patients move through the axSpA treatment algorithm.
Total prevalent cases of axSpA are expected to increase by almost 10% in the US, Japan, and five major EU markets by 2037.
Cosentyx has seen strong uptake due to its ability to meet an unmet medical need in TNF-refractory patients.
A currently limited pipeline leaves room for developers of novel agents targeting the TNF-refractory population.